马来酸罗格列酮对2型糖尿病患者心血管危险因素的影响

Influence of rosiglitazone maleate on cardiovascular risk factors in patients with type 2 diabetes

目的研究马来酸罗格列酮对2型糖尿病患者心血管危险因素C反应蛋白(CRP)、尿微量白蛋白(MAU)、臂踝脉搏波传导速度(baPWV)的影响。方法60例2型糖尿病患者在原有治疗的基础上加用马来酸罗格列酮,加用前及加用治疗6个月后,分别检测空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血三酰甘油(TG)、总胆固醇(TC)、腰/臂比(WHR)、CRP、MAU、baPWV,并比较各指标的变化。结果加用马来酸罗格列酮治疗6个月后,患者FPG、HbA1c、TG、TC、WHR、CRP、MAU、baPWV均下降(P<0.05或P<0.01)。结论马来酸罗格列酮不仅可以改善2型糖尿病者患血糖、血脂代谢,还可以改善2型糖尿病患者的炎症、MAU及动脉硬化。

Objective To observe the effect of rosiglitazone maleate on cardiovascular risk factors：C reactive protein （ CRP）, microaibuminuria （MAU） and brachial-ankle pulse wave velocity （ baPWV ） in patients with type 2 diabetes. Methods 60 patients with type 2 diabetes were treated with rosiglitazone maleate in addition to their previous treatment. Fast plasma glucose （ FPG ） , HbA1 c, triglyceride （ TG ） , total cholesterol （ TC ） , waist-to-hip ratio （ WHR ） , CRP, MAU and baPWV were measured before and after 6 months treated with rosiglitazone maleate. Results The levels of FPG ,HbA1c ,TG,TC ,WHR,CRP,MAU and baPWV decreased significantly after 6 month treated with rosiglitazone maleate treatment（P 〈 0. 01 or P 〈 0. 05 . Conclusion The use of rosiglitazone maieate can not only improve their glucose and lipid metabolism, but aiso improve the inflammation, microalbuminuria and arteriosclerosis in patients with type 2 diabetes.